{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["El-Hachem N"],"funding":["Worldwide Cancer Research"],"pagination":["1154-1164"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11252002"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(7)"],"pubmed_abstract":["Transfer RNA dynamics contribute to cancer development through regulation of codon-specific messenger RNA translation. Specific aminoacyl-tRNA synthetases can either promote or suppress tumourigenesis. Here we show that valine aminoacyl-tRNA synthetase (VARS) is a key player in the codon-biased translation reprogramming induced by resistance to targeted (MAPK) therapy in melanoma. The proteome rewiring in patient-derived MAPK therapy-resistant melanoma is biased towards the usage of valine and coincides with the upregulation of valine cognate tRNAs and of VARS expression and activity. Strikingly, VARS knockdown re-sensitizes MAPK-therapy-resistant patient-derived melanoma in vitro and in vivo. Mechanistically, VARS regulates the messenger RNA translation of valine-enriched transcripts, amo"],"journal":["Nature cell biology"],"pubmed_title":["Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma."],"pmcid":["PMC11252002"],"funding_grant_id":["23-0288"],"pubmed_authors":["Marine JC","Tarassov I","Roncarati P","Capron C","Blomme A","El-Hachem N","Agami R","Nguyen L","Turchetto S","Lavergne A","Thandapani P","Martin-Morales L","Goffin E","Pirotte B","Close P","Rapino F","Leclercq M","Susaeta Ruiz M","Vanleyssem R","Shostak K","Korner PR","Chariot A","Herfs M"],"additional_accession":[]},"is_claimable":false,"name":"Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma.","description":"Transfer RNA dynamics contribute to cancer development through regulation of codon-specific messenger RNA translation. Specific aminoacyl-tRNA synthetases can either promote or suppress tumourigenesis. Here we show that valine aminoacyl-tRNA synthetase (VARS) is a key player in the codon-biased translation reprogramming induced by resistance to targeted (MAPK) therapy in melanoma. The proteome rewiring in patient-derived MAPK therapy-resistant melanoma is biased towards the usage of valine and coincides with the upregulation of valine cognate tRNAs and of VARS expression and activity. Strikingly, VARS knockdown re-sensitizes MAPK-therapy-resistant patient-derived melanoma in vitro and in vivo. Mechanistically, VARS regulates the messenger RNA translation of valine-enriched transcripts, amo","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-02T09:28:54.89Z","creation":"2025-04-06T12:33:27.832Z"},"accession":"S-EPMC11252002","cross_references":{"pubmed":["38849541"],"doi":["10.1038/s41556-024-01439-2"]}}